L'Azienda ospedaliera Santi Antonio e Biagio e Cesare Arrigo è la principale struttura ospedaliera della città di Alessandria. Fondato nel 1567, nella classifica sui migliori ospedali stilata nel 2013 da Agenas il polo alessandrino occupa il terzo posto, dopo il San Raffaele di Milano e gli Spedali Civili di Brescia.

During the past decade, S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 8 clinical trials were completed, i.e. on average, 29.6% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 4 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo" #1 sponsor was "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 28 trials, followed by "Fondazione Italiana Linfomi ONLUS" with 9 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored, "Celgene" with 4 trials sponsored and "Northern Italy Leukemia Group" with 4 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo" #1 collaborator was "AbbVie" with 1 trials as a collaborator, "ERIC Group" with 1 trials as a collaborator, "Fondazione Italiana Linfomi ONLUS" with 1 trials as a collaborator, "GRADE Onlus" with 1 trials as a collaborator and "Janssen-Cilag S.p.A." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo" are "Acute Myeloid Leukemia" (4 trials), "Acute Promyelocytic Leukemia" (3 trials), "Chronic Lymphocytic Leukemia" (3 trials), "Chronic Myeloid Leukemia" (3 trials) and "Lymphoma" (3 trials). Many other conditions were trialed in "S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo" in a lesser frequency.

Most popular intervention types in "S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo" are "Drug" (37 trials), "Other" (9 trials), "Procedure" (3 trials), "Behavioral" (1 trials) and "Genetic" (1 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (6 trials), "Placebo" (4 trials), "Venetoclax" (4 trials), "Cyclophosphamide" (3 trials) and "Doxorubicin" (3 trials). Other intervention names were less common.

The vast majority of trials in "S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo" are 51 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo". 1 are not yet recruiting, 11 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, 1 "Phase 1" clinical trials were conducted, 18 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".